

New Hampshire Medicaid Fee-for-Service Program

Major Adverse Cardiovascular Events (MACE) - Wegovy Criteria

Approval Date: October 1, 2025

Indications

Generic Name (Brand Name)	Covered Indication
semaglutide (Wegovy)	<ul style="list-style-type: none"> Indicated as an adjunct to a reduced-calorie diet and increased physical activity: <ul style="list-style-type: none"> To reduce the risk of major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight

Medications

Brand Names	Generic Names	Dosage
Wegovy	semaglutide	0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, 2.4 mg/ 0.75 mL

Criteria for Approval

- Documented failure of at least a three-month trial on a low-calorie diet (1,200 kcal/day for women, 1,600 kcal/day for men); **AND**
- A regimen of increased physical activity including strength training to prevent lean muscle loss unless medically contraindicated by co-morbidity; **AND**
- Baseline body mass index (BMI) must be at least 27 kg/m² or more; **AND**
- The patient has established cardiovascular (CV) disease; **AND**
- The patient is currently taking guideline-recommended measures for the secondary prevention of a major adverse cardiovascular event (MACE); **AND**
 - A statin at the maximally tolerated dose, ezetimibe, a PCSK9, or a combination of these medications as recommended and tolerated for patients with dyslipidemia
 - Optimizing medications to maintain the appropriate blood pressure goal for patients with hypertension (e.g. an ACE inhibitor or ARB)
 - A beta blocker for patients with a history of MI
 - An anticoagulant or antiplatelet therapy for patients with coronary artery disease (CAD) or other high-risk diagnoses; **AND**

Proprietary & Confidential

All brand names are property of their respective owners.

© 2025 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

6. The patient is at risk for major adverse cardiovascular events (CV death, non-fatal myocardial infarction, or non-fatal stroke); **AND**
7. The patient does **not** have a diagnosis of Type 1 or Type 2 Diabetes Mellitus.

Initial approval will be for 6 months.

Criteria for Renewal

1. Ongoing prescriber documentation of adherence to a low-calorie diet (1,200 kcal/day for women, 1,600 kcal/day for men); **AND**
2. A regimen of increased physical activity and strength training (unless medically contraindicated by co-morbidity); **AND**
3. Ongoing adherence to guideline-recommended measures for secondary MACE prevention); **AND**
4. Patient has not experienced any treatment-restricting adverse effects (e.g., diarrhea, nausea, vomiting, gastroesophageal reflux disease).

Renewal approval will be for 12 months.

Criteria for Denial

1. Prior approval will be denied if the approval criteria are not met; **AND**
2. Patient is using Wegovy solely for chronic weight management.

Revision History

Reviewed by	Reason for Review	Date Approved
DUR Board	New	09/23/2025
Commissioner	Approval	10/01/2025